Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/16374
DC FieldValueLanguage
dc.contributor.authorAna Vavlukisen_US
dc.contributor.authorMarija Vavlukisen_US
dc.contributor.authorAleksandar Dimovskien_US
dc.contributor.authorGordana Petrushevskaen_US
dc.contributor.authorAleksandar Eftimoven_US
dc.contributor.authorSashka Domazetovskaen_US
dc.contributor.authorKristina Mladenovskaen_US
dc.date.accessioned2022-02-03T13:15:03Z-
dc.date.available2022-02-03T13:15:03Z-
dc.date.issued2021-12-30-
dc.identifier.citationVAVLUKIS A, VAVLUKIS M, DIMOVSKI A, PETRUSHEVSKA G, EFTIMOV A, DOMAZETOVSKA S, MLADENOVSKA K. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica.;72(2):303-15.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12188/16374-
dc.description.abstractStatins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data were collected from patients’ records, physical examination, and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given the beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.en_US
dc.language.isoenen_US
dc.publisherWalter de Gruyter GmbHen_US
dc.relation.ispartofActa Pharmaceuticaen_US
dc.subjectrosuvastatinen_US
dc.subjectvascular endothelial growth factoren_US
dc.subjectepidermal growth factoren_US
dc.subjectcardiovascular risken_US
dc.titleAnti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risken_US
dc.typeArticleen_US
dc.identifier.doi10.2478/acph-2022-0018-
dc.identifier.urlhttps://www.sciendo.com/pdf/10.2478/acph-2022-0018-
dc.identifier.volume72-
dc.identifier.issue2-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File Description SizeFormat 
Anti-inflammatory and immunomodulatory effects.pdf525.84 kBAdobe PDFView/Open
Show simple item record

Page view(s)

146
checked on May 4, 2025

Download(s)

19
checked on May 4, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.